CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 41 enrolled
Drug / intervention
BIBW 2992drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00431067
NCT00431067Phase 2Completed
CompareCT.gov

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Boehringer Ingelheim·interventional·Posted Feb 5, 2007·Updated Jun 9, 2014

In Brief

A Phase 2 clinical trial evaluating BIBW 2992 for Breast Neoplasms. Completed, enrolled 41 participants across 12 sites in 2 countries.

Detailed Summary

The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms
CountriesUnited Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 5, 2007
Enrollment StartSep 1, 2006
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 19.4 years ago

Interventions

BIBW 2992drug